Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of warfarin and enoxaparin is a therapeutic anticoagulant regimen used primarily for the treatment of deep vein thrombosis (DVT) and related conditions. This is not a single formulated drug product but rather a combination therapy where both medications are administered concurrently during a transitional period of anticoagulation management. ## Therapeutic Use Warfarin and enoxaparin are commonly used together in a sequential therapy approach. Enoxaparin provides immediate anticoagulation while warfarin, which has a delayed onset of action, gradually reaches therapeutic levels. This combination is specifically indicated for: - Treatment of deep vein thrombosis with or without pulmonary embolism - Management of acute thrombotic conditions requiring immediate and sustained anticoagulation ## Mechanism of Action The combination works through complementary mechanisms: - **Warfarin**: A vitamin K antagonist that inhibits the synthesis of clotting factors II, VII, IX, and X, as well as the anticoagulant proteins C and S - **Enoxaparin**: A low molecular weight heparin that enhances the activity of antithrombin III, inhibiting factor Xa and thrombin ## Administration Protocol When used together: - Enoxaparin is typically initiated immediately - Warfarin therapy is started within 72 hours of beginning enoxaparin - Enoxaparin is continued for a minimum of 5 days and until warfarin achieves a therapeutic INR (2.0-3.0) - The average duration of enoxaparin administration is 7 days, though up to 17 days has been used in clinical trials ## Safety Considerations This combination requires careful monitoring due to: - Increased risk of bleeding complications - Need for regular INR monitoring to adjust warfarin dosing - Potential drug interactions affecting anticoagulation intensity Compared to other anticoagulant combinations, warfarin has a higher drug-drug interaction potential than direct oral anticoagulants, while enoxaparin has fewer drug-drug interactions than other options.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on warfarin + enoxaparin.